| Product Unit Size | Cost | Quantity | Stock |
|---|
GDC-0068 is an orally available Akt inhibitor that exhibits chemotherapeutic activity. GDC-0068 prevents Akt from phosphorylating substrates involved in cell proliferation and the inhibition of pro-apoptotic genes and tumor suppressing proteins.
| Cas No. | 1001264-89-6 |
|---|---|
| Purity | ≥98% |
| Formula | C24H32ClN5O2 |
| Formula Wt. | 458.00 |
| Chemical Name | (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6, 7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-ylamino)propan-1-one |
| IUPAC Name | (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6, 7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2- ylamino)propan-1-one |
| Synonym | RG7440, Ipatasertib |
| Solubility | DMSO 92 mg/mL (200.87 mM) Ethanol 92 mg/mL (200.87 mM) Water Insoluble |
| Appearance | tan powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012 Apr;11(4):873-87. PMID: 22294718.
Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget. 2010 Nov;1(7):530-43. Review. PubMed PMID: 21317449.